The pet medication company generated US$139 million in sales in 2025. This makes Chile a significant market for the group, according to Mariana Cestau, Zoetis’s General Manager for Chile and Peru.
Zoetis is listed on the New York Stock Exchange, and its name combines two concepts. Pronounced (zō – EH-tis), it derives from “zoetic,” meaning “pertaining to life.” With nearly 70 years of history, the company develops medications and solutions for animal health, serving companion animals such as dogs and cats, as well as livestock, including salmon and chickens.
Chile is a key market for the company. While global revenue totaled US$9.5 billion in 2025, Zoetis’s local operations reported US$139 million in sales. This makes Chile a significant market for the group, according to Mariana Cestau, Zoetis’s General Manager for Chile and Peru.
For many people, companion animals—primarily dogs and cats—become another member of the family. In countries with low birth rates, like Chile, where the fertility rate has dropped to 0.99 children per woman, the pet market represents a growing industry.
According to data from the consulting firm Informes de Expertos, the pet care market in Chile reached US$1.9 billion in 2025 and is projected to grow at a compound annual growth rate of 5.9% from 2026 to 2035, when it is expected to exceed US$3.4 billion.
The executive says these figures are key to understanding the growth potential. In Chile, an estimated 8 million pets have owners, yet preventive care rates remain low at around 30%. Cestau market data show that dogs receive an average of 1.4 deworming treatments per year, compared with the monthly frequency that may be recommended, depending on the product and veterinary instructions.
The low coverage of preventive care presents a growth opportunity, as do medications that improve treatment for aging animals. “Monoclonal antibodies for treating pain and arthritis in dogs and cats have been a success,” she explains.
The challenge in the Chilean market, the executive adds, also lies in the other four million animals without owners, mainly dogs. “That is, stray dogs,” she says.
Globally, this business segment accounts for 69% of the Fortune 500 company’s revenue.
The veterinary pharmaceutical market in Chile presents another growth opportunity for the industry. According to Informes de Expertos, the market is valued at US$224.9 million, with projections indicating more than double to exceed US$500 million by 2035.
The consulting firm attributes this growth, in part, to rising pet ownership and increased demand for animal health solutions for livestock.
Livestock, including salmon, chickens, pigs and other livestock, is Zoetis’s second operating segment.
The executive says the challenge is “how we accelerate vaccine adoption to ensure that food remains safe for humans while minimizing or restricting the use of antibiotics to prevent resistance.”
Improving health practices and welfare throughout the production chain aligns with the company’s One Health concept, which integrates human, animal and environmental health.
To this end, the company allocates nearly US$700 million annually to global research and development (R&D) for medications, vaccines, diagnostic tools and new therapies. Its portfolio also includes genomic solutions for livestock selection.
Overall, the outlook in Chile is for continued strong growth. In 2025, the company reported a 24% increase in local sales, and over the past three years, it has doubled the workforce in its livestock business.
Source: Forbes.